Scalp cooling for more than 90 minutes ranked best against chemotherapy hair loss

Design

Systematic review and network meta-analysis of randomised trials

Population

736 patients receiving chemotherapy across 12 trials of 9 interventions

Primary outcome

Hair preservation, as defined by each trial

Effect

Prolonged cooling vs usual care RR 24.66 (7.07–86.05); vs traditional RR 2.13 (1.15–3.93)

A systematic review and network meta-analysis included 12 randomised trials (736 patients) of interventions to prevent chemotherapy-induced alopecia. It compared scalp hypothermia by how long cooling continued after the infusion — short (up to 45 minutes), traditional (46–90) and prolonged (over 90) — with scalp compression, four drugs and usual care.

Prolonged cooling was associated with much better hair preservation than usual care (RR 24.7, 95% CI 7.1–86.1) and than traditional-duration cooling (RR 2.13, 1.15–3.93). Its advantage over short cooling was not significant (RR 2.06, 0.78–5.39). Drug options fared poorly against it. Most trials were at high risk of bias, and certainty was rated low to very low.

Scalp cooling is already the established option; this suggests the post-infusion phase may matter. In India, scalp cooling devices are available in few centres, and cost and chair time are real constraints. Where it is offered, it is reasonable to discuss a longer post-infusion period, while being honest that the evidence on duration is weak.

• Discuss scalp cooling with patients before starting chemotherapy regimens that commonly cause hair loss.
• Where scalp cooling is used, consider continuing it for more than 90 minutes after the infusion.
• Tell patients that no drug option prevented hair loss as well as cooling in these trials.
• Set expectations: hair preservation definitions varied, and partial loss can still occur.

Why it matters

Hair loss is one of the most feared effects of chemotherapy, and cooling duration is easy to change.

Don't overread it

Most trials were at high risk of bias; the duration effect rests on low to very low certainty evidence.

The statistics, in plain English

A risk ratio of 24.7 with an interval from 7 to 86 means a large benefit but a very imprecise estimate, because few small trials fed this comparison. When certainty is graded low or very low, the true effect could be substantially different.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.